Philips Signs Multiyear Strategic Partnership Agreement for Connected Care Solutions with 28-hospital Dutch SAZ Group

February 4, 2021

Philips notes the partnership will encompass the monitoring, observation and self-management of patients throughout the entire care journey, both inside and outside the hospitals, supported by Philips advanced patient monitoring and population health management solutions.

“The SAZ unites 28 regional hospitals, which are together making the move from being hospitals to a health organization,” says Bert Kleinlugtenbeld, President of the SAZ. “In doing so, the strength of the SAZ is that we act together and learn from each other. Our strategic direction is to move care to the patient’s home wherever possible. We also see an important role for prevention. In making this move, removing the burden from the patient and the care provider is central. With Philips, we will do this by using the latest technological innovations in the field of patient monitoring and population health management, strengthening our cooperation in patient-centric care.”

“We look forward to continue working with the regional SAZ hospitals to provide the right care in the right place,” says Léon Kempeneers, General Manager Health Systems Philips Benelux. “Through this collaboration with the SAZ, our connected care solutions can be scaled up more easily within the Netherlands’ regional hospitals. Our goal is to improve care by using technology to relieve the burden on patients and caregivers. By improving outcomes through the early detection of patient deteriorations and reducing readmissions, we ultimately hope to reduce the pressure on staff.”

Prevent ICU re-admissions

During the course of 2021 about ten SAZ hospitals will start the collaboration focused either on hospital care or care in the community. In-hospital applications will include early detection of patient deterioration on nursing wards using Philips’ IntelliVue Guardian Solution, which the Bravis hospital in Bergen op Zoom and Roosendaal, the Netherlands, already has experience of using. The Bravis hospital is also already using Philips’ wearable biosensor and will use it to make a better connection between patient monitoring in the hospital’s ICU and its nursing wards, reducing the length of stay in the ICU and helping to prevent ICU re-admissions. In addition, the solution will help a patient to return to a long term care setting or their own home. By creating an automatic link between the Philips biosensor, the Philips IntelliVue Guardian software and the hospital’s EMR system, the organization aims to reduce the time nurses spend on administration.

Self-management for patients

Other hospitals will start projects in the field of home monitoring and self-management for patients, something that IJsselland Hospital in Capelle aan den IJssel, the Netherlands, is already doing with Philips as part of a telemonitoring project for patients with heart failure and COPD. Patients measure their blood pressure and weight at home, and this data is monitored by heart failure nurses in the hospital. Patients also receive additional information and tips on how to manage their condition. The aim is to prevent readmissions and increase patient engagement, something that will be supported by Philips’ patient-centric Engage platform, which provides patient and provider access to an overview of the patient’s health information.

The SAZ has experience with multiparty collaborations to improve healthcare. In 2017 the 28 hospitals started the company BeterDichtbij BV. BeterDichtbij is now used by 35 hospitals in the Netherlands. As part of the strategic collaboration between SAZ a connection will be realized between BeterDichtbij and the Philips Engage platform.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Led by researchers at NYU Grossman School of Medicine, the study results add to evidence that neighboring brain regions, the inferior frontal gyrus and the motor cortex, play an important role in such planning before words are said aloud. Both are part of the folded top layers of the brain, or cerebral cortex, which has long been known to control the muscle (motor) movements in the throat and mouth needed to produce speech. Less clear until now was how closely these regions determine the mix of sounds and words people want to say aloud, the authors report.
PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy